NASDAQ: IXHLIncannex Healthcare Inc Stock
$2.72+0.01 (+0.37%)
Updated Apr 8, 2026
IXHL Price
$2.72
Fair Value Price
N/A
Market Cap
$32.49M
52 Week Low
$2.40
52 Week High
$49.80
P/E
-0.12x
P/B
0.44x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$48.50M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.02
Operating Cash Flow
-$18M
Beta
0.38
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IXHL Overview
Incannex Healthcare Ltd develops and sells medicinal cannabinoid products in Australia. It offers pharmaceutical-grade cannabinoid products under the Incannex brand name. Incannex Healthcare has a partnership with The Alfred Hospital and Novotech, and the Monash Trauma Group at the Department of Neuroscience, Monash University. Known as Impression Healthcare Ltd. until 2020, Incannex Healthcare was incorporated in 2001 and is based in Sydney, Australia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IXHL's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
IXHL
Ranked#52 of 54
Ranked#52 of 54
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $12.71 | A | |
| $31.94 | A | |
| $30.52 | A |
Be the first to know about important IXHL news, forecast changes, insider trades & much more!
IXHL News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IXHL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IXHL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IXHL is good value based on its book value relative to its share price (0.44x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.64x)
P/B vs Industry Valuation
IXHL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more IXHL due diligence checks available for Premium users.
Valuation
IXHL fair value
Fair Value of IXHL stock based on Discounted Cash Flow (DCF)
Price
$2.72
Fair Value
$12.71
Undervalued by
78.59%
IXHL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IXHL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.12x
Industry
-168.55x
Market
29.79x
IXHL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.44x
Industry
1.64x
IXHL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IXHL's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.5M
Profit Margin
0%
IXHL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$75.0M
Liabilities
$1.6M
Debt to equity
0.02
IXHL's short-term assets ($74.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IXHL's short-term assets ($74.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IXHL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.6M
Investing
-$4.0k
Financing
$927.0k
IXHL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IXHL vs Pharmaceutical Stocks
Incannex Healthcare Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.